Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

3. fázisú, kettős vak, placebo-kontrollos vizsgálat (A rész) nyílt kiterjesztéssel (B. rész), az MM120 értékelése placebóval összehasonlítva generalizált szorongásos zavarban

2026. szeptember 24. frissítette: Definium Therapeutics US, Inc.

3. fázisú, többközpontú, randomizált, kettős vak, placebo-kontrollos, 12 hetes vizsgálat (A rész) 40 hetes nyílt elrendezésű kiterjesztéssel (B rész), amely az orális MM120 hatékonyságát és biztonságosságát értékeli a placebóval összehasonlítva Generalizált szorongásos zavarban szenvedő felnőttek kezelése - Voyage

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage

A tanulmány áttekintése

Állapot

Aktív, nem toborzó

Beavatkozás / kezelés

Részletes leírás

The study will enroll up to 200 participants aged 18 to 74 years, inclusive with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) confirmed primary diagnosis of GAD and a minimum HAM-A total score of at least 20 at Screening and Baseline without clinically relevant medical or psychiatric history.

The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating DT120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment. During this phase, participants will be monitored and evaluated for potential treatment with DT120 based on pre-specified safety and symptom severity criteria.

Tanulmány típusa

Beavatkozó

Beiratkozás (Tényleges)

214

Fázis

  • 3. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

    • Arizona
      • Gilbert, Arizona, Egyesült Államok, 85234
        • Lighthouse Psychiatry
      • Scottsdale, Arizona, Egyesült Államok, 85022
        • Scottsdale Research Institute
    • California
      • La Jolla, California, Egyesült Államok, 92037
        • Kadima Neuropsychiatry Institute
      • San Francisco, California, Egyesült Államok, 94158
        • UCSF Department of Neurology
      • Santa Monica, California, Egyesült Államok, 90404
        • Psychedelic Science Institute
    • Colorado
      • Denver, Colorado, Egyesült Államok, 80209
        • Mountain View
    • Florida
      • Jacksonville, Florida, Egyesült Államok, 32256
        • Clinical Neuroscience Solutions Inc.
      • Lauderhill, Florida, Egyesült Államok, 33319
        • Segal Trials
    • Georgia
      • Atlanta, Georgia, Egyesült Államok, 30331
        • Atlanta Center for Medical Research
      • Decatur, Georgia, Egyesült Államok, 30030
        • iResearch Atlanta
      • Savannah, Georgia, Egyesült Államok, 31405
        • CenExel iResearch, LLC
    • Illinois
      • Chicago, Illinois, Egyesült Államok, 60640
        • Uptown Research Institute
    • Massachusetts
      • Boston, Massachusetts, Egyesült Államok, 02116
        • Adams Clinical Boston
      • Watertown, Massachusetts, Egyesült Államok, 02472
        • Adams Clinical Watertown
    • New Jersey
      • Marlton, New Jersey, Egyesült Államok, 08053
        • Hassman Research Institute
    • New York
      • New York, New York, Egyesült Államok, 10021
        • Spectrum Neuroscience and Treatment Institute
      • New York, New York, Egyesült Államok, 10032
        • New York State Psychiatric Institute (NYSPI)
      • New York, New York, Egyesült Államok, 10029
        • Adams Clinical Harlem
      • The Bronx, New York, Egyesült Államok, 10461
        • Adams Clinical Bronx
    • Ohio
      • Cleveland, Ohio, Egyesült Államok, 44113
        • Cleveland Clinic Lutheran Hospital
    • Oregon
      • Portland, Oregon, Egyesült Államok, 97210
        • Summit Headlands LLC
    • Pennsylvania
      • Moosic, Pennsylvania, Egyesült Államok, 18507
        • Scranton Medical Institute
      • Philadelphia, Pennsylvania, Egyesült Államok, 19104
        • Adams Clinical Philadelphia
    • South Carolina
      • North Charleston, South Carolina, Egyesült Államok, 29405
        • Coastal Carolina Research Center
    • Tennessee
      • Memphis, Tennessee, Egyesült Államok, 38119
        • Clinical Neuroscience Solutions, Inc.
    • Texas
      • Austin, Texas, Egyesült Államok, 78712
        • University of Texas at Austin
      • Austin, Texas, Egyesült Államok, 78759
        • BioBehavioral Research of Austin
      • Austin, Texas, Egyesült Államok, 78737
        • Austin Clinical Trial Partners
      • Dallas, Texas, Egyesült Államok, 75231
        • FutureSearch Trials of Dallas, LLC
      • DeSoto, Texas, Egyesült Államok, 75115
        • Adams Clinical Dallas
    • Utah
      • Draper, Utah, Egyesült Államok, 84020
        • Cedar Clinical Research
      • Orem, Utah, Egyesült Államok, 84058
        • Inner Space Research
    • Vermont
      • Bennington, Vermont, Egyesült Államok, 05201
        • Memory Clinic Inc.
    • Washington
      • Seattle, Washington, Egyesült Államok, 98104
        • Seattle Neuropsychiatric Treatment Center

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

18 év (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  1. Diagnosis of GAD per DSM-5
  2. Male or female aged 18 to 74
  3. HAM-A Total Score ≥20

Exclusion Criteria:

  1. Certain psychiatric disorders (other than generalized anxiety disorder)
  2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
  3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
  4. Any clinically significant unstable illness

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Hármas

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Placebo Comparator: Arm 1 - Placebo

A substance that is designed to have no therapeutic value

A substance that is designed to have no therapeutic value

Kísérleti: Arm 2 - 100µg DT120

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

Más nevek:
  • lizergid-tartarát
  • MM120
  • LSD D-Tartrate

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12
Időkeret: Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Baseline to Week 12

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Clinical Global Impression - Improvement (CGI-I) Scale score at each timepoint assessed during the 12-week double-blind period
Időkeret: Day 2 to Week 12

The CGI-I scale is used to measure the clinician's assessment of how much the participant's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises one item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening.

Day 2 to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
Időkeret: Baseline to Week 12

The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
Időkeret: Baseline to Week 12

The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)
Időkeret: Baseline to Week 12

The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS).

Baseline to Week 12
Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period
Időkeret: Baseline to Week 12

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

Baseline to Week 12
Percent of men and women with normal and abnormal sexual functioning at each timepoint assessed during the double-blind period
Időkeret: Baseline to Week 12

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

Baseline to Week 12
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in MADRS total score
Időkeret: Baseline to Week 52

The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
Időkeret: Baseline to Week 52

The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
Időkeret: Baseline to Week 52

The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in WPAI-SHP
Időkeret: Baseline to Week 52

The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in EQ-5D-5L
Időkeret: Baseline to Week 52

The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS).

Baseline to Week 52
Percent men and women with normal and abnormal sexual functioning at each timepoint assessed during the open-label period
Időkeret: 40 week open label period

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

40 week open label period
Change from Baseline in HAM-A total score at Week 8, Week 4, Week 2, and Week 1
Időkeret: Week 8, Week 4, Week 2, and Week 1

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Week 8, Week 4, Week 2, and Week 1
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 12-week double-blind period
Időkeret: Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Baseline to Week 12
HAM-A remission (total score ≤7) at each timepoint assessed during the 12-week double-blind treatment period
Időkeret: Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score
Időkeret: Baseline to Week 12

The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in -Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)
Időkeret: Baseline to Week 12

The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study.

Baseline to Week 12
Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period
Időkeret: Day 1 to Week 52

Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period

Day 1 to Week 52
Time to first treatment or lack of efficacy in the open-label period (Part B)
Időkeret: Day 1 to Week 52

Measured as time from first dosing in the Double-blind period to participant meeting HAM-A criteria for re-dose or meeting criteria for lack of efficacy

Day 1 to Week 52
Need for DT120 treatment as assessed by the average number of DT120 treatments during the study
Időkeret: Day 1 to Week 52

Average number of treatments assessed from first dose in the double-blind period through completion of the open label extension.

Day 1 to Week 52
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 40-week open-label period
Időkeret: 40 week open label period

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

40 week open label period
HAM-A remission (total score ≤7) at each timepoint assessed during the 40-week open-label period
Időkeret: 40 week open label period

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

40 week open label period
CSFQ-14 total score at each timepoint assessed during the open-label period
Időkeret: 40 week open label period

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

40 week open label period

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Publikációk és hasznos linkek

A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2024. december 11.

Elsődleges befejezés (Tényleges)

2026. július 15.

A tanulmány befejezése (Becsült)

2027. április 1.

Tanulmányi regisztráció dátumai

Először benyújtva

2024. december 16.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2024. december 16.

Első közzététel (Tényleges)

2024. december 18.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. szeptember 25.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. szeptember 24.

Utolsó ellenőrzés

2026. június 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Egyéb vizsgálati azonosító számok

  • MM120-300

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Igen

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel